Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Felix Oehme

Peter Kolkhof

Kai Thede

Hanno Wild

Ingo Flamme

Jens-Kerim Ergüden

Joachim Schuhmacher

Mario Jeske

Friederike Stoll

Hartmut Beck

Metin Akbaba

Jörg Keldenich

Karl-Heinz Schlemmer

Lars Bärfacker

Thomas Krahn

Henning Steinhagen

Gunter Karig

Barbara Albrecht

Michael Gerisch

Alexander Kuhl

Joachim Hütter

Axel Jensen

Joachim Mittendorf

Joachim H&uuml;tter

Michael H&auml;rter

Gabriele Handke

Gabriele Handke-Ergüden

Werner Nickl

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dipyridyl-dihydropyrazolones and use thereof

Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors

Dipyridyl-dihydropyrazolones and their use

This application relates to compounds of formula (I) below in which the several variable groups are as defined in the specification and claims, to methods of preparing these materials, to pharmaceutical compositions containing these materials, and to methods of using these materials to treat ischaemia or reperfusion damage.

Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS)

Substituted amidoalkyl-uracils and their use

Growing community of inventors

Wuppertal, Germany

Felix Oehme